If a patient has atrial fibrillation or high risk coronary syndromes, would you consider replacing ibrutinib with acalabrutinib or zanubrutinib in Triangle regimen for MCL?
Answer from: at Community Practice
Generally, if a patient is significantly symptomatic or intolerant due to atrial fibrillation, or other arrhythmia or even heart failure, it is reasonable to consider a next generation BTKI (acalabrutinib or zanubrutinib). As a cardiologist, I will defer to my cancer colleagues on efficacy across ad...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Yes, but anymore, it depends on whether I can get it paid for!